ArticleDermatologic therapy2020
Psoriasis, COVID-19, and acute respiratory distress syndrome: Focusing on the risk of concomitant biological treatment.
Article in Dermatologic therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A systematic review and meta-analysis of investigating the mutual impact of COVID-19 and psoriasis: Focusing on COVID-19 course in psoriasis and the opinion on biologics in this setting.Immunity, inflammation and disease · 2023Pooled it
- Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.Journal of the American Academy of Dermatology · 2020Guideline
- Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study.The Journal of allergy and clinical immunology · 2021Trial
- Perception and Impact of COVID-19 Pandemic in Psoriasis Patients: Data from the German PsoBest and the CoronaBest Registries.Psoriasis (Auckland, N.Z.) · 2024Article
- Management of Psoriasis During the Coronavirus Disease 2019 Pandemic.The Journal of clinical and aesthetic dermatology · 2021Review
- The COVID-19 pandemic and its skin effects.Canadian family physician Medecin de famille canadien · 2021Review
- COVID-19 in Immunocompromised Hosts: What We Know So Far.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Review
- Biologics for Psoriasis During the COVID-19 Pandemic.Frontiers in medicine · 2021Review
- The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments.Vaccines · 2020Review
- COVID-19 and immune-mediated inflammatory diseases: Why don't our patients get worse?Autoimmunity reviews · 2020Article
- Coronavirus disease 2019 (COVID-19) rash in a psoriatic patient treated with Secukinumab: Is there a role for Interleukin 17?Dermatologic therapy · 2020Article
- Comment on "Psoriasis, COVID-19, and acute respiratory distress syndrome: Focusing on the risk of concomitant biological treatment".Dermatologic therapy · 2020Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.